Jump to content

Search the Community

Showing results for tags 'lungevity'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • WELCOME NEW MEMBERS!
    • INTRODUCE YOURSELF!
  • STORIES OF SURVIVORSHIP
    • SHARE YOUR LUNG CANCER STORY
  • DISCUSSION FORUMS
    • GENERAL
    • LC SURVIVORS
    • NSCLC GROUP
    • SCLC GROUP
    • LUNG CANCER MUTATIONS
    • IMMUNOTHERAPY
    • CAREGIVER RESOURCE CENTER
    • PALLIATIVE CARE
  • LUNG CANCER Q & A
    • LUNG CANCER NAVIGATOR
    • LUNG CANCER 101
  • NEWS / ADVOCACY
    • LUNG CANCER IN THE NEWS
    • CLINICAL TRIALS
    • FOUNDATION NEWS
    • ADVOCACY
    • CONFERENCES
  • LIVING WELL
    • HEALTHY LIVING / RECIPES
    • HOPE
    • JUST FOR FUN
  • SUPPORT / GROUPS
    • SUPPORT RESOURCES
    • SUPPORT GROUPS
  • GRIEF / RESOURCES
    • GRIEF
  • ABOUT THIS MESSAGE BOARD
    • FEATURES AND SUPPORT
    • TERMS OF USE

Blogs

  • An Advocate's Perspective
  • Cheryncp123's Blog
  • Lung Cancer Stories
  • PeggieH
  • Stay The Course
  • Stage IV Treatment With S.B.R.T.
  • Caregivers Connection
  • Spree
  • Volunteer Voices

Calendars

There are no results to display.


Found 65 results

  1. Here is the weekly clip report: Health “The Difference Between Small Cell and Non-Small Cell Lung Cancer” http://www.health.com/smoking/small-cell-lung-cancer-non-small-cell-lung-cancer Genetic Engineering & Biotechnology News “CRISPR Screen Identifies Top 100 Essential Genes for Cancer Immunotherapy” http://www.genengnews.com/gen-news-highlights/crispr-screen-identifies-top-100-essential-genes-for-cancer-immunotherapy/81254771 Healio “FDA Grants Orphan Drug Designation to Tesevatinib for EGFR-Mutated Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{1be8c744-6be6-42fa-b024-6e12a8bd01f5}/fda-grants-orphan-drug-designation-to-tesevatinib-for-egfr--mutated-non-small-cell-lung-cancer Targeted Oncology “Combinations, Biomarkers Will Be Future Focus in Metastatic NSCLC, Expert Says” http://www.targetedonc.com/news/combinations-biomarkers-will-be-future-focus-in-metastatic-nsclc-expert-says Onc Live “Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC” http://www.onclive.com/web-exclusives/sequencing-switches-intriguing-combos-being-debated-in-alk-nsclc U.S. News & World Report “Best Hospitals for Cancer” http://health.usnews.com/best-hospitals/rankings/cancer Health “7 Causes of Lung Cancer in Non-Smokers” http://www.health.com/smoking/causes-of-lung-cancer-non-smoker MIT Technology Review “Cancer Blood Tests Score Early Success” https://www.technologyreview.com/s/608601/cancer-blood-tests-score-early-success/ Cure “Expert Discusses Stem Cell Research and Personalizing Lung Cancer Care” http://www.curetoday.com/articles/expert-discusses-stem-cell-research-and-personalizing-lung-cancer-care OncLive “Molecular Targets Could Be Unraveled for Patients with Non-Driver NSCLC” http://www.onclive.com/web-exclusives/molecular-targets-could-be-unraveled-for-patients-with-nondriver-nsclc OncLive “Liquid Biopsies, NGS Expected to Become Standard in Lung Cancer” http://www.onclive.com/web-exclusives/liquid-biopsies-ngs-expected-to-become-standard-in-lung-cancer
  2. Here is the weekly clip report: Healio “FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{ff2af53b-37fe-4249-8680-63b558b163a7}/fda-grants-breakthrough-therapy-designation-to-imfinzi-for-non-small-cell-lung-cancer Specialty Pharmacy Times “Concurrent Chemotherapy, High-Dose Proton Beam Radiotherapy Show Promise in Advanced Lung Cancer” https://www.specialtypharmacytimes.com/news/concurrent-chemotherapy-high-dose-proton-beam-radiotherapy-show-promise-in-advanced-lung-cancer Medscape “In Immunotherapy, Approved Biomarkers Pose Many Problems” http://www.medscape.com/viewarticle/883451 Times Leader “Dance Club Supports LUNGevity Foundation” http://timesleader.com/community-features/669953/dance-club-supports-lungevity-foundation-4 Cancer Therapy Advisor “Study Predicts Important Role for SABR in Treatment of Early-Stage NSCLC” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-sabr-treatment-important-role/article/678775/ U.S. News & World Report “Back Pain and Other Unusual Signs of Lung Cancer” http://health.usnews.com/health-care/patient-advice/articles/2017-08-01/back-pain-and-other-unusual-signs-of-lung-cancer New York Magazine “Here’s What Not to Say to Someone with Cancer” http://nymag.com/scienceofus/article/heres-what-not-to-say-to-someone-with-cancer.html Targeted Oncology “Options for Upfront Treatment of ALK-Rearranged NSCLC” http://www.targetedonc.com/case-based-peer-perspectives/lung-cancer/langer-alk-nsclc/options-for-upfront-treatment-of-alk-rearranged-nsclc Wicked Local – Scituate “Scituate Man Throws Out Red Sox Pitch and Raises Awareness for Lung Cancer” http://scituate.wickedlocal.com/news/20170803/scituate-man-throws-out-red-sox-pitch-and-raises-awareness-for-lung-cancer OncLive “FDA Grants Frontline Alectinib Priority Review for ALK-Positive NSCLC” http://www.onclive.com/web-exclusives/fda-grants-frontline-alectinib-priority-review-for-alkpositive-nsclc Cancer Network “Concurrent Chemo, Proton Therapy Promising in Advanced Lung Cancer” http://www.cancernetwork.com/news/concurrent-chemo-proton-therapy-promising-advanced-lung-cancer Specialty Pharmacy Times “FDA Grants Durvalumab Breakthrough Therapy Designation for Locally-Advanced Lung Cancer” https://www.specialtypharmacytimes.com/news/fda-grants-durvalumab-breakthrough-therapy-designation-for-locally-advanced-lung-cancer Everyday Health “Five Reasons to Be Optimistic About Lung Cancer” https://www.everydayhealth.com/lung-cancer/living-with/reasons-optimistic-about-lung-cancer/
  3. Here is the weekly clip report: Patient Daily “FDA Approves AstraZeneca's Tagrisso for Treating Certain Forms of Lung Cancer” http://patientdaily.com/stories/511146319-fda-approves-astrazeneca-s-tagrisso-for-treating-certain-forms-of-lung-cancer Medical News Today “Small Cell Lung Cancer: Cause of Treatment Resistance Discovered” http://www.medicalnewstoday.com/articles/318547.php Medical Xpress “Breaking the Genetic Resistance of Lung Cancer and Melanoma” https://medicalxpress.com/news/2017-07-genetic-resistance-lung-cancer-melanoma.html CNBC “Google Parent Company Invested in a Hot Cancer-Testing Start-Up and Built It a Dedicated Lab” http://www.cnbc.com/2017/07/24/alphabet-verily-invests-in-freenome-builds-lab-on-google-campus.html Across America Patch “Increasing Hope for Some Patients With a Common Type of Lung Cancer” https://patch.com/us/across-america/increasing-hope-some-patients-common-type-lung-cancer Benzinga “Lung Cancer Mutation Consortium Finds Breast Cancer Driver, HER2, in 3 Percent of Lung Cancers” https://www.benzinga.com/pressreleases/17/07/p9833596/lung-cancer-mutation-consortium-finds-breast-cancer-driver-her2-in-3-pe Cure “Being a Sibling of a Cancer Patient” http://www.curetoday.com/community/kim-johnson/2017/07/being-a-sibling-of-a-cancer-patient
  4. Heather Hogan's Story

    I was 52, a wife, mom and teacher when diagnosed with stage 3a NSC Adenocarcinoma lung cancer in September 2012. I had no symptoms and did not fit the criteria of a lung cancer candidate. An observant radiologist had noticed a small shadow in my lower right lobe when viewing an unrelated abdominal scan in 2010. Because I didn’t fit any of the LC criteria, no specialist or surgeon thought that it would be lung cancer. They adopted a “wait and see” plan using two six-month scans and then moved to a one-year scan at which that point indicated that my “nothing” spot had in fact grown and was probably lung cancer. My world had been turned upside down. I quickly had surgery to remove my bottom right lobe and several lymph nodes. Unfortunately, cancer was found in the lymph nodes and the tumor. This led to four rounds of chemotherapy (Cisplatin and Navelbine) and 25 treatments of radiation along with all the mental and physical issues that many people can only imagine. Cancer can be a very lonely disease even when you have a ton of support. I couldn’t find survivors in my area so I began searching out on-line groups that I could communicate with about my disease. This is where I discovered LUNGevity! The members of this group and all those associated with the organization wrapped their cyber arms around me and welcomed me into their world. This was literally a life-saving experience for me and continues to be part of my daily communication. Two years ago, people in the group began speaking about the National HOPE Summit in Washington, D.C. and how beneficial it was for both patients and caregivers. Because I am Canadian, I inquired as to whether my husband and I could attend. I was told of course we could! My husband and I attended HOPE Summit and that experience has changed my life. Meeting other survivors and hearing from physicians and researchers empowered me to return to my own country and begin asking questions about lung cancer research and most importantly, begin my work as a lung cancer advocate. The Summit allowed me to meet so many people who are advocates not only for their own health but also for lung cancer research and advocacy work. These people meet with politicians, organize, and participate in lung cancer fundraisers and teach so many of us about treatment options. Although Canada does not have as large a network, there is a small group of us who have been empowered to meet with politicians, educate and support others with the disease and spread the word about early lung cancer diagnosis, all because of our experience at a LUNGevity HOPE Summit. Education is power but knowing you are part of a strong, supportive, and knowledgeable group of individuals is invaluable. Thank you LUNGevity!
  5. Charlotte Jamison

    By: Deborah R. Burns “Everybody can be great. Because anybody can serve. You only need a heart full of grace, A soul generated by love.” - Dr. Martin Luther King, Jr. Charlotte Jamison is many things: a Christian, a mother, a teacher, a friend, and a volunteer. Over the past two years, Charlotte has volunteered her time and talents to assist in the efforts of the LUNGevity Foundation’s Annual Breathe Deep DC 5K Walk. Charlotte serves as the backbone and chief fundraiser for Team Open Technology Group: (OTG) United for A Cure. Charlotte and my family have been friends longer than I can remember. She and my husband Leon had a special relationship. I still remember how they would often laugh together, share experiences, and enjoy working together on church projects. After my husband was diagnosed with lung cancer, she was the key person who supported me and walked me through that unforgettable journey. Since my husband’s death in 2011, she continues to be a huge inspiration in my healing. A member of New Canaan Baptist Church in Washington, DC. (Gregory M. Sims, Pastor), Charlotte has engaged the entire congregation in being part of this important cancer-fighting effort. She sets up a beautifully decorated table each year to receive donations and to recruit walkers for the OTG Team. She and her helpers work tirelessly documenting information, promoting the cause, and speaking to individuals about the walk. On the day of the walk she always arrives with a smile and eager to help. She immediately begins handing out goodie bags, gathering our Team and rallying “Team Spirit”. Many of the volunteers from other teams admire her enthusiasm and dedication for the cause. She inspires through example. I can never thank her enough for all that she brings to our Team and fighting this disease that claims thousands of lives each year. Did I mention that she’s 80 years young! God strengthens her to do His work. She often says “As long as the good Lord enables me to work, I’m going to work.” Open Technology Group’s cup runneths over for having Charlotte Jamison serve as a volunteer for OTG: United For A Cure. We are truly blessed by having her.
  6. Here is the weekly clip report: WSMV-TV “Knoxville Girl's Lemonade Stand Raises More Than $4K for Mom's Cancer Fight” http://www.wsmv.com/story/35893378/knoxville-girls-lemonade-stand-raises-more-than-4k-for-moms-cancer-fight PR Newswire “LUNGevity Foundation and 32 Cancer-Related Patient Advocacy and Professional Organizations Jointly Oppose Senate's Revised BCRA” http://www.prnewswire.com/news-releases/lungevity-foundation-and-32-cancer-related-patient-advocacy-and-professional-organizations-jointly-oppose-senates-revised-bcra-300489076.html The Commercial Appeal (USA Today) “New Baptist Project Catches Lung Cancer in Early Stages” http://www.commercialappeal.com/story/news/2017/07/17/new-baptist-project-catches-lung-cancer-early-stages/469710001/ Healio “Genomic Testing for Non-Small Cell Lung Cancer Underused in Community-Based Practices” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{f5d98ce8-8ab1-4d4c-b52e-c85b4ee1533f}/genomic-testing-for-non-small-cell-lung-cancer-underused-in-community-based-practices Midland Daily News “Breakthrough Lung Cancer Detection Equipment Now Available Locally” http://www.ourmidland.com/news/article/Breakthrough-lung-cancer-detection-equipment-now-11291920.php Medical Xpress “Cause of Chemo Resistance in Small Cell Lung Cancer Discovered” https://medicalxpress.com/news/2017-07-chemoresistance-small-cell-lung-cancer.html American Journal of Managed Care “LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer” http://www.ajmc.com/journals/evidence-based-oncology/2017/July-2017/LDH-Levels-Could-Predict-irAEs-Associated-With-Checkpoint-Inhibition-and-Radiotherapy-in-Lung-Cancer US News “Understanding Targeted Therapies for Lung Cancer” http://health.usnews.com/health-care/patient-advice/articles/2017-07-18/understanding-targeted-therapies-for-lung-cancer Healio “Maintenance Pembrolizumab Benefits Certain Patients with Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{748e9e43-ff90-44ef-af7b-a53722107e65}/maintenance-pembrolizumab-benefits-certain-patients-with-small-cell-lung-cancer Cure Today “Persisting Gaps in Cancer Care Affect Patient Outcomes” http://www.curetoday.com/advocacy/CancerSupportC/persisting-gaps-in-cancer-care-affect-patient-outcomes Oncology Practice “Immune Signature Shows Good Prognostic Performance in Early-Stage NSCLC” http://www.mdedge.com/oncologypractice/article/142757/lung-cancer/immune-signature-shows-good-prognostic-performance-early MedScape “ASCO Addresses High Cost of Cancer Drugs” http://www.medscape.com/viewarticle/883115
  7. Here is the weekly clip report: Healio “Brigatinib Confers Positive Outcomes in ALK-Positive Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{d8bfdb5c-8523-4a48-b4c7-555cb37b3c54}/brigatinib-confers-positive-outcomes-in-alk-positive-nonsmall-cell-lung-cancer CNBC “Roche Unveils Advancements in Breast and Lung Cancer Drugs” http://www.cnbc.com/video/2017/06/05/roche-unveils-advancements-in-breast-and-lung-cancer-drugs.html Medical Xpress “Greater Access to Genetic Testing Needed for Cancer Diagnosis and Treatment” https://medicalxpress.com/news/2017-07-greater-access-genetic-cancer-diagnosis.html Healio “Ceritinib Demonstrates Activity in ROS1-Positive Non-Small Cell Lung Cancer https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{217b896c-1abb-4689-a58c-31ae7c608d5c}/ceritinib-demonstrates-activity-in-ros1-positive-nonsmall-cell-lung-cancer Cancer Network “Is one immunotherapy for lung cancer better than the rest?” http://www.cancernetwork.com/videos-lung-cancer/one-immunotherapy-lung-cancer-better-rest Farragut Press “Lemons for LUNGevity” http://www.farragutpress.com/articles/2017/07/6353.php Cure “Examining the Role of Blood-Based Biomarkers in Lung Cancer” http://www.curetoday.com/articles/examining-the-role-of-bloodbased-biomarkers-in-lung-cancer Cancer Therapy Advisor “Proton-Beam Therapy May Be Effective for Limited-Stage Small-Cell Lung Cancer” http://www.cancertherapyadvisor.com/lung-cancer/proton-beam-therapy-effective-small-cell-lung-cancer/article/673364/ Specialty Pharmacy Times “Measuring T Cell Levels May Help Identify Patient Response to Immunotherapy” https://www.specialtypharmacytimes.com/news/measuring-t-cell-levels-may-help-identify-patient-response-to-immunotherapy Specialty Pharmacy Times “Nanotechnology Could Change the Future of Disease Treatment” https://www.specialtypharmacytimes.com/news/nanotechnology-could-change-the-future-of-disease-treatment KUSA-TV “Idris Elba Opens Up About Father's Death and Going Through a Midlife Crisis: 'I Wasn't Even Living’” http://www.9news.com/entertainment/entertainment-tonight/idris-elba-opens-up-about-fathers-death-and-going-through-a-midlife-crisis-i-wasnt-even-living/454711270
  8. Here is the weekly clip report: Genetic Engineering and Biotechnology News “Discovery of New Immune Cell May Improve Treatment of Lung Cancer Patients” http://www.genengnews.com/gen-news-highlights/discovery-of-new-immune-cell-may-improve-treatment-of-lung-cancer-patients/81254527 Specialty Pharmacy Times “Alectinib Slashes Risk of Disease Progression or Death by Half in Patients with NSCLC” https://www.specialtypharmacytimes.com/news/alectinib-slashes-risk-of-disease-progression-or-death-by-half-in-patients-with-nsclc Cancer Network “ASTRO Issued New Guideline on Use of SBRT in Early-Stage Lung Cancer” http://www.cancernetwork.com/news/astro-issued-new-guideline-use-sbrt-early-stage-lung-cancer Radiology Business “Dozens of House Members Caution against Further Cuts to Lung Screening Reimbursement” http://www.radiologybusiness.com/topics/policy/dozens-house-members-caution-against-further-cuts-lung-screening-reimbursement Targeted Oncology “The Debate over Upfront Use of Newer Targeted Agents in NSCLC” http://www.targetedonc.com/publications/targeted-therapy-news/2017/June-2017/the-debate-over-upfront-use-of-newer-targeted-agents-in-nsclc Genome Web “In Efforts to Ramp Up Adoption of Liquid Biopsies, Lung Cancer Becomes Proving Ground” https://www.genomeweb.com/molecular-diagnostics/efforts-ramp-adoption-liquid-biopsies-lung-cancer-becomes-proving-ground Mayo Clinic News Network “Blood-Based Lung Cancer Test Shows Promise: Mayo Clinic Radio Health Minute” http://newsnetwork.mayoclinic.org/discussion/blood-based-lung-cancer-test-shows-promise-mayo-clinic-radio-health-minute/ Cancer Network “Atezolizumab Active in Advanced Lung Cancer, PD-L1 Predicts Response” http://www.cancernetwork.com/lung-cancer/atezolizumab-active-advanced-lung-cancer-pd-l1-predicts-response Harvard Business Review “New Approach to Safely Sharing Cancer Patients’ Data” https://hbr.org/2017/06/a-new-approach-to-safely-sharing-cancer-patients-data Cancer Therapy Advisor “Once-Daily Radiotherapy Not Superior to Twice-Daily in SCLC” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-sclc-radiotherapy-superior-twice-daily/article/670091/ Medical Xpress “Catching Cancer Earlier—a New Frontier for Early Detection Research” https://medicalxpress.com/news/2017-06-cancer-earliera-frontier-early.html Lung Cancer News Today “Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage” https://lungcancernewstoday.com/2017/06/22/entinostat-keytruda-clinical-trial-nsclc-proceed-next-stage/ Medical Xpress “First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients” https://medicalxpress.com/news/2017-06-first-line-immunotherapy-treatment-survival-subset.html PR Newswire “FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies” http://www.prnewswire.com/news-releases/fda-approves-first-companion-diagnostic-test-to-simultaneously-screen-for-multiple-non-small-cell-lung-cancer-therapies-300478690.html Cure Today “Combination Approved for BRAF-Positive Lung Cancer” http://www.curetoday.com/articles/combination-approved-for-braf-positive-lung-cancer Healio “10 Updates in Immunotherapy Research” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{4f336a9e-848e-49d8-8fe1-a43d04bbce72}/10-updates-in-immunotherapy-research
  9. Permission to Feel

    I noticed something recently at the in-person support group I facilitate. Caregivers in my group didn't speak up about issues or feelings unless the facilitator or group leader mentioned them first. "Like Jan said, I have feelings of ____ too." After the third time, it occured to me that caregivers are either waiting to have their feelings validated by someone else or didn't realize they had been feeling those feelings. I remember being a caregiver for my father and how all-encompassing that was. Nothing else mattered to me at the time. Everything was about my dad's cancer, his feelings, his happiness, his peace and comfort. I don't think I got more than 2-3 hours of sleep a night during those 11 months- there was just so much to do! I completely lost myself and any sense of "me" during my caregiving. I would never consider taking time for myself, taking a break or openly expressing my frustrations and concerns- that would be selfish- afterall, I wasn't the one in treatment with cancer. I wasn't the one fighting for my life, right? If given the opportunity then, would I have taken advantage of caregiver resources or support groups? Would I even know what I was feeling or how to describe it? Until we are able to have caregiver-only support groups in every community, how can we give caregivers the encouragement or "permission" to put a voice to what they are feeling? How do we as caregivers divorce ourselves from the guilt that accompanies self-care? Thoughts?
  10. MONDAY, JUNE 5 Reuters “Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial” https://www.reuters.com/article/us-health-cancer-roche-pfizer-idUSKBN18W1HH Forbes “A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us” https://www.forbes.com/sites/matthewherper/2017/06/03/a-new-cancer-drug-helped-almost-everyone-who-took-it-almost-heres-what-it-teaches-us/#677ea9e6b25f The Telegraph (UK) “Cancer Patients Who Enter Their Symptoms into an App Live Longer than Expected, Study Suggests” http://www.telegraph.co.uk/science/2017/06/04/cancer-patients-enter-symptoms-app-live-longer-expected-study/ Patient Daily “FDA OKs Novartis’ Zykadia for Metastatic Lung Cancer Affecting the Brain”http://patientdaily.com/stories/511122036-fda-oks-novartis-zykadia-for-metastatic-lung-cancer-affecting-the-brain TUESDAY, JUNE 6 Drug Discovery & Development “ASCO 2017: Investigational Agent Improves Survival Outcomes for EGFR-Positive Lung Cancer” https://www.dddmag.com/article/2017/06/asco-2017-investigational-agent-improves-survival-outcomes-egfr-positive-lung-cancer The Washington Post “8 Things Doctors are Buzzing about at the Biggest Cancer Meeting” https://www.washingtonpost.com/news/to-your-health/wp/2017/06/06/7-attention-grabbing-topics-at-the-nations-biggest-cancer-meeting/?utm_term=.39f88e8f0ae0 WEDNESDAY, JUNE 7 Fannin Sentinel “Lungevity: Shining Light on the Invisible Disease” http://fanninsentinel.news/?p=7581 PR Newswire “Julie R. Brahmer, MD., MSc, is recognized by Continental Who's Who” http://www.prnewswire.com/news-releases/julie-r-brahmer-md-msc-is-recognized-by-continental-whos-who-300469906.html Healio “Pembrolizumab Reduces Need for Second-Line Therapy in Advanced NSCLC” http://www.healio.com/hematology-oncology/lung-cancer/news/online/{7d9e7f9c-c66a-4f06-9ab3-e95da959cad5}/pembrolizumab-reduces-need-for-second-line-therapy-in-advanced-nsclc ASCO Daily News “Studies Explore Targeted Therapies in Lung Cancer” https://am.asco.org/studies-explore-targeted-therapies-lung-cancer THURSDAY, JUNE 8 The New York Times “Cancer Drug Proves to Be Effective Against Multiple Tumors” https://www.nytimes.com/2017/06/08/health/cancer-drug-keytruda-tumors.html?_r=0 The New York Times “When Your Personal War on Cancer Is Exhausting” https://www.nytimes.com/2017/06/08/well/live/when-your-personal-war-on-cancer-is-exhausting.html?_r=0 EurekAlert “Scientific Advances in Thoracic Oncology in 2016 Highlighted by the IASLC” https://www.eurekalert.org/pub_releases/2017-06/iaft-sai060817.php FRIDAY, JUNE 9 Healio “Primary NSCLC May Be Underdiagnosed Among Patients with Metastatic Renal Cell Carcinoma” http://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{97a56d74-d2e8-44d3-942a-7e8f636341b7}/primary-nsclc-may-be-underdiagnosed-among-patients-with-metastatic-renal-cell-carcinoma Cure Today “Expert Discusses the Future of EGFR+ and ALK+ Lung Cancer” http://www.curetoday.com/articles/expert-discusses-the-future-of-egfr-and-alk-lung-cancer USA Today “’How Long Have I Got?’: Why Many Cancer Patients Don’t Have Answers ” https://www.usatoday.com/story/news/2017/06/09/kaiser-how-long-have-got-doc-why-many-cancer-patients-dont-have-answers/102518488/
  11. Here is the weekly clip report: TUESDAY, MAY 30 Miami Herald “Using Your Immune System to Fight Cancer is Showing Significant Promise” http://www.miamiherald.com/living/health-fitness/article152969614.html Cancer Network “Certinib Gets First-Line FDA Approval ALK-Positive Lung Cancer” http://www.cancernetwork.com/lung-cancer/ceritinib-gets-first-line-fda-approval-alk-positive-lung-cancer WEDNESDAY, MAY 31 CHEST (American College of Chest Physicians) “What You Need to Know About Biopsies for Lung Cancer” http://www.chestnet.org/News/Blogs/CHEST-Thought-Leaders/2017/05/What-you-need-to-know-about-biopsies OncLive “Modern Biopsy Techniques Changing the Scope of Lung Cancer Diagnosis” http://www.onclive.com/web-exclusives/modern-biopsy-techniques-changing-the-scope-of-lung-cancer-diagnoses Reuters “Cancer Meeting to Provide Clues on Future Immunotherapy Combos” https://www.reuters.com/article/us-health-cancer-immunotherapy-idUSKBN18R1EA Genome Web “Vanderbilt Team Using Mass Spec to Research Cancer Immunotherapy” https://www.genomeweb.com/proteomics-protein-research/vanderbilt-team-using-mass-spec-research-cancer-immunotherapy THURSDAY, JUNE 1 Lung Cancer News Today “Trilaciclib Improves Chemo’s Effectiveness Against Small Cell Lung Cancer, Study Finds” https://lungcancernewstoday.com/2017/06/01/study-shows-combination-of-triliciclib-and-chemo-benefits-lung-cancer-patients/ PR Newswire “Roche Announces FDA Approval of Companion Diagnostic to Identify ALK-Positive Non-Small Cell Lung Cancer Patients” http://www.prnewswire.com/news-releases/roche-announces-fda-approval-of-companion-diagnostic-to-identify-alk-positive-non-small-cell-lung-cancer-patients-300466815.html Business Wire “Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy R&D Collaboration” http://www.businesswire.com/news/home/20170531005968/en/Atreca-Dana-Farber-Cancer-Institute-Establish-Broad-Cancer NBC News “More New Cancer Drugs Mean Higher Costs But Also Longer Lives” http://www.nbcnews.com/health/health-news/more-new-cancer-drugs-mean-higher-costs-also-longer-lives-n767156 FRIDAY, JUNE 2 Bloomberg “A Hot-Cancer Drug Race Keeps Getting More Crowded” https://www.bloomberg.com/news/articles/2017-06-02/immune-oncology-drug-trials-are-getting-crowded Business Insider “The FDA and a $1.2 Billion Startup Are Analyzing How Drugs Are Used After Approval – and It Could One Day Change How we Treat Cancer” http://www.businessinsider.com/flatiron-health-collaboration-with-fda-data-at-asco-2017-6 U.S. News & World Report “As Scientists Train the Immune System to Fight Cancer, Others Look to Combat Costs” https://www.usnews.com/news/healthcare-of-tomorrow/articles/2017-06-02/as-scientists-train-the-immune-system-to-fight-cancer-others-look-to-combat-costs
  12. Soccer Camp for a Cause

    50% of the proceeds from this soccer camp in Columbia, MD, will be donated to LUNGevity Foundation! Soccer Camp.pdf
  13. MONDAY, MAY 22 USA Today “Hope Summit is Just that for Lung Cancer Survivors” https://www.usatoday.com/story/life/2017/05/22/hope-summit-just-lung-cancer-survivors/101710746/ Patient Daily “AstraZeneca Reports Positive Results in Trial Using Imfinzi in Stage III Non-Small Cell Lung Cancer Cases” http://patientdaily.com/stories/511116688-astrazeneca-reports-positive-results-in-trial-using-imfinzi-in-stage-iii-non-small-cell-lung-cancer-cases TUESDAY, MAY 23 Business Insider “The FDA just Took an Entirely New Approach Approving a Cancer Drug” http://www.businessinsider.com/fda-approves-cancer-drug-based-on-genetic-markers-2017-5 Clinical Oncology News “ASCO Report: Gefitinib beats Chemo After Surgery in NSCLC” http://www.clinicaloncology.com/Lung-Cancer/Article/05-17/ASCO-Report-Gefitinib-Beats-Chemo-After-Surgery-in-NSCLC-/41434 U.S. News & World Report “Advice for Lung Cancer Caregivers” http://health.usnews.com/health-care/patient-advice/articles/2017-05-23/advice-for-lung-cancer-caregivers WEDNESDAY, MAY 24 Medical Xpress “Using a Genetic Signature to Overcome Chemotherapy-Resistant Lung Cancer” https://medicalxpress.com/news/2017-05-genetic-signature-chemotherapy-resistant-lung-cancer.html Reuters “Brief – Onocyte Presents Positive Lung Cancer Blood Test Data at American Thoracic Society” https://www.reuters.com/article/brief-oncocyte-presents-positive-lung-ca-idUSFWN1IO0IS THURSDAY, MAY 25 Genome Web “OncoCyte Lung Cancer Test Validation Data Bodes Well for Launch This Year” https://www.genomeweb.com/molecular-diagnostics/oncocyte-lung-cancer-test-validation-data-bodes-well-launch-year PR Newswire “NCCN Awards Grants to Investigators at Member Institutions to Study Osimertinib in Lung Cancer” http://www.prnewswire.com/news-releases/nccn-awards-grants-to-investigators-at-member-institutions-to-study-osimertinib-in-lung-cancer-300463998.html FRIDAY, MAY 26 Cancer Therapy Advisor “Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-Associated Survival” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-radiotherapy-might-improve-immune-checkpoint-blockade-survival/article/664708/ Cure Today “FDA Approves Zykadia for Metastatic Non-Small Cell Lung Cancer” http://www.curetoday.com/articles/fda-approves-zykadia-for-metastatic-nonsmall-cell-lung-cancer Patient Daily “Gefitinib Shown to Delay Recurrence of Lung Cancer Following Surgery” http://patientdaily.com/stories/511119431-gefitinib-shown-to-delay-recurrence-of-lung-cancer-following-surgery The ASCO Post “The Ongoing Challenges of Lung Cancer Screening” http://www.ascopost.com/issues/may-25-2017/the-ongoing-challenges-of-lung-cancer-screening/ ASCO Daily News “Targeting RET Rearrangements in Non–Small Cell Lung Cancer” https://am.asco.org/targeting-ret-rearrangements-non-small-cell-lung-cancer
  14. MONDAY, MAY 15 Medscape “What’s New for Lung Cancer? Stay Tuned for ASCO 2017” http://www.medscape.com/viewarticle/879994 TUESDAY, MAY 16 Healio “Survivors of Hodgkin Lymphoma Have Increased Risk for Second Cancer” http://www.healio.com/hematology-oncology/lymphoma/news/in-the-journals/{099e0b29-8044-4d8c-8215-f0691027f7d8}/survivors-of-hodgkin-lymphoma--increased-risk-for-second-cancer Forbes “How AI and Deep Learning is now Used to Diagnose Cancer” https://www.forbes.com/sites/bernardmarr/2017/05/16/how-ai-and-deep-learning-is-now-used-to-diagnose-cancer/#45695214c783 WEDNESDAY, MAY 17 Medical Xpress “Brigatinib First to Offer Over 1-Year Control of ALK-Positive Lung Cancer Post-Crizotinib” https://medicalxpress.com/news/2017-05-brigatinib-year-alk-positive-lung-cancer.html U.S. News & World Report “Cancer Fatigue: So Tired by Treatment” http://health.usnews.com/health-care/patient-advice/articles/2017-05-17/cancer-fatigue-so-tired-by-treatment Boston Globe “Two MGH Doctors Offer Step-by-Step Advice for Living with Cancer” https://www.bostonglobe.com/magazine/2017/05/17/two-mgh-doctors-offer-step-step-advice-for-living-with-cancer/rC0eryFm4VbgffHQfsNLLJ/story.html THURSDAY, MAY 18 Reuters “Merck, Incyte Immunotherapy Combination Effective in Lung Cancer Study” http://www.reuters.com/article/health-cancer-merck-incyte-idUSL2N1IJ1QC Medical Xpress “Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer” https://medicalxpress.com/news/2017-05-therapy-recurrence-intermediate-stage-lung-cancer.html FRIDAY, MAY 19 Reuters “CHMP Backs Novartis's Zykadia for First-Line Use in Lung Cancer” http://www.reuters.com/article/us-novartis-zykadia-idUSKCN18F1FK News-Medical “Researchers Discover Novel Mechanism That Causes Malignant Pleural Effusion in Lung Cancer Patients” http://www.news-medical.net/news/20170519/Researchers-discover-novel-mechanism-that-causes-malignant-pleural-effusion-in-lung-cancer-patients.aspx
  15. Last week, the FDA approved the first immunotherapy combination – using immunotherapy with chemotherapy. Now, Opdivo*, in combination with ALIMTA* and carboplatin, may be recommended for patients with metastatic non-squamous non-small cell lung cancer in the first-line setting. This combination is only approved for patients who do not have a molecular target, such as EGFR, ALK, or ROS1. The approval has generated a lot of questions in the survivor community. Do you have questions? post them below. Register now to join us TOMORROW. It's going to be a great live conversation. https://attendee.gotowebinar.com/register/6168809270748272387
  16. Here is the weekly clip report: MONDAY, MAY 8 Medical Xpress “Study Identifies New Target to Fight Prostate, Lung Cancer” https://medicalxpress.com/news/2017-05-prostate-lung-cancer.html WTIU-FM (Indiana Public Media) “New Study To Examine Why Patients Choose Lung Cancer Screenings” http://indianapublicmedia.org/news/study-examine-patients-choose-lung-cancer-screenings-119528/ Cancer Network “Checkpoint Inhibitors Improve Response to Salvage Chemotherapy in NSCLC” http://www.cancernetwork.com/lung-cancer/checkpoint-inhibitors-improve-response-salvage-chemotherapy-nsclc TUESDAY, MAY 9 US News & World Report “Here’s How to Manage Lung Cancer Side Effects” http://health.usnews.com/health-care/patient-advice/articles/2017-05-09/heres-how-to-manage-lung-cancer-side-effects New York Post “How Assembling the Right Cancer Team May Save Your Life” http://nypost.com/2017/05/09/how-assembling-the-right-cancer-team-may-save-your-life/ WEDNESDAY, MAY 10 WETA-TV (PBS—Washington, DC) “This Cuban Lung Cancer Drug Is Giving Some U.S. Patients Hope” http://www.pbs.org/newshour/bb/cuban-lung-cancer-drug-giving-u-s-patients-hope/ Cure “Will Immunotherapy Move into All Lung Cancer Patient Populations?” http://www.curetoday.com/articles/will-immunotherapy-move-into-all-lung-cancer-patient-populations THURSDAY, MAY 11 Lung Cancer News Today “Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer” https://lungcancernewstoday.com/2017/05/11/lung-cancer-platform-target-selector-developed-biocept-undergo-clinical-trial/ Reuters “U.S. FDA Approves Merck Immunotherapy/Chemo Combo for Lung Cancer” http://www.reuters.com/article/us-merck-co-lungcancer-idUSKBN1862Y2 FRIDAY, MAY 12 Fortune “Why Merck’s Keytruda Just Became a Lung Cancer Game Changer” http://fortune.com/2017/05/11/fda-lung-cancer-merck-keytruda/ Cancer Therapy Advisor “Alectinib Beats Crizotinib in ALK-positive Non-small Cell Lung Cancer” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-alectinib-crizotinib-compare-treatment/article/661354/ Eurek Alert “Invasive Lung Cancer Cells Display Symbiosis -- Key to metastasis” https://www.eurekalert.org/pub_releases/2017-05/ehs-ilc050917.php Reuters “AstraZeneca’s Durvalumab Shown in Trial to Reduce Risk of Death from Lung Cancer” http://www.reuters.com/article/astrazeneca-cancer-idUSFWN1IE06Z
  17. Advocates are courageous and brave as they raise awareness or work tirelessly to change injustices and create a better world. Most people become advocates because they were personally affected by the cause they are fighting for. While they have smiles on their faces and work to inspire...there's a part of their hearts that are always grieving for the love they lost or the life that once was. At least thats true for me- even after 15 years. While our personal experience fuels us during advocacy events and awareness days we are also acutely aware of the absence of those who were lost to the disease and reminded that a part of our life is forever changed. Advocacy is a way to turn a terrible life experience into education, awareness, and support for soneone facing similar challenges. Advocacy events and activities can be personally rewarding and advocacy efforts can assist others and even change their lives. Being an advocate is amazing and meaningful. While I celebrate the progress I've been a part of and the lives I've helped to change, a part of me is alwaying grieving a little bit. I've learned that grief is most definitely one emotion that fuels advocacy. As long as I advocate for people with lung cancer, I will never stop grieving for my dad. Everything I advocate for reminds me that he's no longer here. Part of me finds comfort that he is still "with" me after all these years while other relatives have long stopped saying his name. While I'm on a mission to provide all these things to improve a patients survivorship, I'm reminded that my dad never had these things and he did not have a fair shot at survival. It's really bittersweet. Even though there is a an undercurrent of sadness-- turning tragedy into purpose and a mission honors my dad. Its also the most rewarding feeling to serve others and help to change their lives
  18. Lung Cancer Navigator App Aims to Help Patients Understand Disease Oncology Nurse Advisor: LUNGevity, a lung cancer-focused nonprofit organization, has launched a new mobile application designed to help patients with lung cancer better understand their disease and make living with lung cancer less daunting.1 The mobile app, called Lung Cancer Navigator, is a customizable app that provides the latest medical and treatment information related to patients' specific lung cancer diagnosis. In addition, it offers tools for organizing customized care, managing multiple medications, and describing and tracking symptoms. Patients may use the app to input reminders and keep a list of questions for their next doctor visit. http://www.oncologynurseadvisor.com/navigator-notes/mobile-app-provides-assistance-to-lung-cancer-patients/article/631136/
  19. When diagnosed with lung cancer, there are often more questions than answers. How do you get information you need to make the best decisions about your care? When exactly does survivorship begin? Katie Brown, Vice President of Support and Survivorship Programs at LUNGevity Foundation, shares her personal connection to lung cancer and why she is so passionate about helping patients find the best resources at the time they need them the most. https://www.patientpower.info/video/empowering-lung-cancer-patients-through-advocacy
  20. Here is the weekly clip report: TUESDAY, MAY 2 US News “The Link Between Air Pollution and Lung Cancer” http://health.usnews.com/health-care/patient-advice/articles/2017-05-02/the-link-between-air-pollution-and-lung-cancer Cure “Adding Mindfulness: Innovation for an Optimal Preoperative Rehabilitation Before Lung Cancer Resection” http://www.curetoday.com/publications/cure/2017/spring-lung-2017/adding-mindfulness-innovation-for-an-optimal-preoperative-rehabilitation-before-lung-cancer-resection WEDNESDAY, MAY 3 Cure “Speaking the Language of Lung Cancer” http://www.curetoday.com/publications/cure/2017/spring-lung-2017/speaking-the-language-of-lung-cancer NPR “Urgent Care Services for Cancer Patients Offer a Gentler ER Alternative” http://www.npr.org/sections/health-shots/2017/05/03/526594004/urgent-care-services-for-cancer-patients-offer-a-gentler-er-alternative Medscape “The Evolving Landscape for EGFR Mutation-Positive Advanced NSCLC: Clarifying a New Standard of Care” http://www.medscape.com/viewarticle/879482 Fortune Magazine “This Is What’s Missing in the Data-Centric Approach to Cancer” http://fortune.com/2017/05/03/brainstorm-health-cancer-data/ Forbes “Joe Biden on His New Cancer Initiative, Drug Prices and Donald Trump” http://fortune.com/2017/05/03/joe-biden-trump-cancer-drug-prices/ THURSDAY, MAY 4 Vanderbilt News “Lovly Elected to American Society for Clinical Investigation” https://news.vanderbilt.edu/2017/05/04/lovly-elected-to-american-society-for-clinical-investigation/ Targeted Oncology “Expert Highlights Benefits of Next-Generation Sequencing for NSCLC” http://www.targetedonc.com/news/expert-highlights-benefits-of-nextgeneration-sequencing-for-nsclc FRIDAY, MAY 5 Huffington Post “Using AI to Spot Lung Cancer” http://www.huffingtonpost.com/entry/using-ai-to-spot-lung-cancer_us_590c8e92e4b056aa2363d424 The Science Times “Air Pollution Induces Lung Cancer Too: Here’s What You Should Know” http://www.sciencetimes.com/articles/14333/20170505/air-pollution-induces-lung-cancer-here-what-know.htm
  21. MONDAY, APRIL 17 Onc Live “Immunotherapy Agents, Combinations to Compete for Frontline NSCLC” http://www.onclive.com/web-exclusives/immunotherapy-agents-combinations-to-compete-for-frontline-nsclc Reuters “OncoMed's lung cancer drug fails mid-stage study, shares tumble” http://www.reuters.com/article/us-oncomed-pharms-study-idUSKBN17J0ZK Cure Today “All in the Family: Discussing Screenings and Preventative Surgery for Inherited Cancers” http://www.curetoday.com/publications/cure/2017/spring-2017/all-in-the-family-discussing-screenings-and-preventative-surgery-for-inherited-cancers?p=1 TUESDAY, APRIL 18 Chicago Tribune “Breathe Deep North Shore Aimes to Focus Attention on Lung Cancer” http://www.chicagotribune.com/suburbs/highland-park/news/ct-dfr-breathe-deep-north-shore-preview-tl-0420-20170417-story.html US News – Health “New Treatments for Lung Cancer” http://health.usnews.com/health-care/patient-advice/articles/2017-04-18/new-treatments-for-lung-cancer Lung Cancer News Today “Opdivo More Than Tripled 5-Year Survival Rates in NSCLC Patients in Phase 1 Study” https://lungcancernewstoday.com/2017/04/18/opdivo-tripled-five-year-survival-rates-in-nsclc-patients-in-phase-1-study/ WEDNESDAY, APRIL 19 Media News Today “Lung Cancer: Blood Test May Lead to Earlier, Personalized Treatment” http://www.medicalnewstoday.com/articles/317010.php The Huffington Post “’State of the Air 2017’ – Who’s Best and Worst?” http://www.huffingtonpost.com/entry/state-of-the-air-2017-whos-best-and-worst_us_58f76453e4b071c2617f014b THURSDAY, APRIL 20 Medical Xpress “New Test for Early Detection of Lung Cancer Measures Tiny Charges in the Composition of Breath” https://medicalxpress.com/news/2017-04-early-lung-cancer-tiny-composition.html FRIDAY, APRIL 21 Cancer Therapy Advisor “In Focus: Atezolizumab for Non-small Cell Lung Cancer” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-atezolizumab-focus-treatment/article/652028/
  22. MONDAY, APRIL 10 Fox Sports “This Week’s Bow Tie Represents … LUNGevity” http://www.foxsports.com/mlb/story/this-weeks-bow-tie-represents-lungevity-040817 The Huffington Post “Getting Screened: Taking Charge Of Your Own Health May Save Your Life” http://www.huffingtonpost.com/entry/getting-screened-taking-charge-of-your-own-health_us_58eb6776e4b0acd784ca5a15 TUESDAY, APRIL 11 Lohud (USA Today) “Pulmonary Rehabilitation Proves Effective for Some Lung Cancer Patients” http://www.lohud.com/story/sponsor-story/newyork-presbyterian-hospital/2017/04/11/pulmonary-rehabilition-lung-cancer-patients/100115990/ Lung Cancer News Today “Genentech’s Alecensa Superior to Xalkori in Newly Diagnosed ALK+ Advanced NSCLC Patients” https://lungcancernewstoday.com/2017/04/11/alk-positive-advanced-nsclc-therapy-alecensa-superior-xalkori/ WEDNESDAY, APRIL 12 PR Newswire “Alice Shaw of Massachusetts General Hospital and Harvard University Joins the LUNGevity Foundation Scientific Advisory Board” http://www.prnewswire.com/news-releases/alice-shaw-of-massachusetts-general-hospital-and-harvard-university-joins-the-lungevity-foundation-scientific-advisory-board-300438369.html Forbes “Which Cancer Patients Will be Helped by Powerful Immune Drugs” https://www.forbes.com/sites/elaineschattner/2017/04/12/which-cancer-patients-will-be-helped-by-powerful-immune-drugs-this-test-may-tell/#48bf4853689c THURSDAY, APRIL 13 Onc Live “Liquid Biopsy Testing Detects Recurrence in High-Risk NSCLC” http://www.onclive.com/publications/oncology-live/2017/vol-18-no-07/liquid-biopsy-testing-detects-recurrence-in-highrisk-nsclc FRIDAY, APRIL 14 Washington Life Magazine “LUNGevity Musical Celebration of Hope Gala” http://washingtonlife.com/calendar/
  23. LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Alice T. Shaw, MD, PhD, has joined LUNGevity’s Scientific Advisory Board, a group of 20 world-renowned scientists and researchers that guides LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and Career Development Awards. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Dr. Shaw performs clinical and translational research. Her clinical research focuses on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research focuses on understanding and making clear the mechanisms of resistance to targeted therapies; she is currently developing novel combination treatment strategies. Her research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements. “We could not be happier that Dr. Shaw has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “She is a brilliant thinker, an innovator, and a compassionate advocate for her patients. In particular, her groundbreaking work that led to the development of Xalkori® has extended and improved the lives of many NSCLC patients. Her expertise and counsel will advance LUNGevity’s goal to increase and improve survivorship for those affected by lung cancer.” Read the full press release here.
  24. Here is the weekly clip report: MONDAY, APRIL 3 PR Newswire “LUNGevity Launches Groundbreaking Platform for Patient Voices” http://www.prnewswire.com/news-releases/lungevity-launches-groundbreaking-platform-for-patient-voices-300433478.html ABC News “U.S. Cancer Deaths are Decreasing, Study Finds” http://abcnews.go.com/Health/us-cancer-deaths-decreasing-study-finds/story?id=46490447 The Blade “UT Researchers Map Genetic Code to Determine Cancer Risk” http://www.toledoblade.com/Medical/2017/04/03/UT-researchers-map-genetic-code-to-determine-cancer-risk.html TUESDAY, APRIL 4 WWTV-TV (CBS—Traverse City, MI) “LUNGevity Launches Groundbreaking Platform for Patient Voices” http://www.9and10news.com/story/35057597/lungevity-launches-groundbreaking-platform-for-patient-voices Lung Cancer News Today “Screening Initiative in Georgia Finds Twice the Lung Cancer Rate of Previous Efforts” https://lungcancernewstoday.com/2017/04/04/lung-cancer-screening-initiative-twice-rate/ WEDNESDAY, APRIL 5 OncLive “Frontline Setting for ALK+ NSCLC Set to Undergo Shift” http://www.onclive.com/web-exclusives/frontline-setting-for-alk-nsclc-set-to-undergo-shift Oncology Nursing News “Nivolumab 5-Year Survival Rate Exceeds Expectations in NSCLC” http://nursing.onclive.com/web-exclusives/nivolumab-5year-survival-rate-exceeds-expectations-in-nsclc THURSDAY, APRIL 6 CNBC “The Land of Vikings May Hold the Cure for Cancer” http://www.cnbc.com/2017/04/06/the-land-of-the-vikings-may-hold-the-cure-for-cancer.html MIT News “Study Helps Explain Varying Outcomes for Cancer, Down Syndrome” http://news.mit.edu/2017/chromosome-number-varying-outcomes-cancer-down-syndrome-0406 Lung Cancer News Today “Alecensa Improves Progression-Free Survival in Certain Lung Cancer Patients” https://lungcancernewstoday.com/2017/04/06/lung-cancer-therapy-alecensa-inhibits-progression-of-disease/ FRIDAY, APRIL 7 “When Health Advocates Can’t Save Themselves” http://health.usnews.com/health-care/patient-advice/articles/2017-04-07/when-health-advocates-cant-save-themselves
  25. We have several possible media opportunities for individuals who are using the Lung Cancer Navigator App to help manage their/their loved one's lung cancer diagnosis. If you are interested in sharing your story and helping to raise awareness for this resource, please respond to this thread and we will be in touch with more information. If you would like to learn more about the Lung Cancer Navigator App and how to download it for free from the Apple or Google Play stores, please visit LUNGevity's website. Thank you! Lauren -- Digital Community Manager LUNGevity Foundation
×